Duloxetine, known commercially as Cymbalta, has been shown to relieve neuropathic pain caused by chemotherapy in 59 percent of patients in a recent study at the University of Michigan. Lead study author, Ellen M. Lavoie Smith, PhD, and researcher at the U-M Comprehensive Cancer Center, says, “These drugs don’t work for everyone. The good news …
Antidepressant Helps Relieve Pain from Chemotherapy Read More »
EpiCept Corp. has received formal scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) that are aligned with the recent guidance given by the U.S. FDA regarding the development of AmiKet, for the treatment of CIPN. EpiCept has reported significant postiive results in the treatment of …
With breast cancer survivors estimated at 2.8 million, more women are living with the chronic effects of their cancer treatments. The American Cancer Society convened a panel of experts from the University of North Carolina (UNC) to review current practices and make recommendations for rehabilitation. Deborah Mayer, PhD, UNC, says, “As more women are surviving …
International Panel Recommends New Model for Breast Cancer Care Read More »
Early screening seems to be having a positive impact on the incidence of new cases of colorectal cancer over that past 2 decades. Unfortunately, the treatment of choice, Oxaliplatin, produces serious side effects such as chemo-therapy induced peripheral neuropathy. Clinical trials have been done that concluded a calcium and magnesium infusion, given before the Oxaliplatin …
Dr. Daniela Salvemini, associate professor of pharmacolgical and physiolgical science at SLU School of Medicine has been awared a grant to research a way to help ease, or stop, pain during chemotherapy. Pain is the primary reason patients stop chemotherapy treatments. Chemo-therapy induced peripheral neuropathy causes a feeling of burning and inflammation in extremities. READ …
St. Louis University Researcher Targets Pain in Chemotherapy Read More »
EpiCept Corporation announced that it has filed for Fast Track designation for AmiKet, their new topical cream to be used in the treatment of chemotherapy-induced peripheral neuropathy. The Fast Track program, created by the FDA, is designed to facilitate development and expedite review of drugs intended to treat serious or life-threatening conditions and address unmet …
EpiCept Files for AmiKet™ Fast Track Designation Read More »
In a study from the Colorado Cancer Center, results have shown that using Oxaliplatin for the treatment of colorectal cancer causes Oxaliplatin-induced neurotoxicity (OXIN). One way to avoid immediate symptoms from the drug is to use a ‘stop and go’ treatment cycle giving the drug with breaks in between treatments. The study was published in …
DARA BioSciences, recently awarded fast track designation from the FDA for the development of their new drug for the treatment of neuropathic pain, has just released the results of a Phase II safety and efficacy study. The study showed KRN5500 demonstrated a statistically significant improvement in the relief of neuropathic pain versus a placebo. READ …
Kaiser Health just release information about studies which indicate that rehabilitation for cancer patients, during and after chemotherapy treatments, are necessary to regain enough functionality to perform ordinary activities. One patient realized that after 6 weeks of therapies for peripheral neuropathy and balance issues, she “didn’t feel so limited by side effects any longer.” READ …
Cancer Patients Could Benefit from Greater Use of Rehabilitation Read More »
Researchers at University of Wisconsin Carbone Cancer Center are testing a new pain therapy device for patients with nerve pain following chemotherapy treatments. With 40 percent of chemotherapy patients developing neuropathy it is an important step in finding new, effective treatments. Forty patients will be part of the clinical trial. READ MORE Source: University of Wisconsin
